Company intelligence / Profile preview

Amerimmune

McLean, Virginia, United States

Ownership: Private
Development stage: Other

Overview

Amerimmune completed a successful Phase 1 clinical trial jointly with Histogen Inc. for Emricasan as a caspase inhibitor targeting COVID-19; results showed safety and hints of efficacy. The company is developing diagnostic panels for Long COVID and immune disorders, and is expanding diagnostic offerings to toxicology, cancer genetics, and pharmacogenomics

Therapeutic areas: ImmunologyInfectious DiseasesRare Diseases
Modalities: Small moleculeDiagnostics
Industry: Biotech

Partnerships

Histogen Inc. (historic, development of Emricasan for COVID-19)Quest Diagnostics (sample collection network for Long COVID panel)

Beyond the preview

Go deeper on Amerimmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amerimmune.

Explore the full profile